Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Replicative Cell Senescence02:15

Replicative Cell Senescence

4.2K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
4.2K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

8.6K
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
8.6K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Host metabolism can produce many indoles and phenols independently of the microbiome.

Nature metabolism·2026
Same author

The patterns of microbial community distribution and co-occurrence in water columns and sediments of Haima cold seep.

Microbiology spectrum·2026
Same author

GATA4 loss promotes mutant <i>Kras</i>-driven pancreatic ductal adenocarcinoma in the absence of canonical precursor lesions.

bioRxiv : the preprint server for biology·2026
Same author

Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.

Cancer cell·2026
Same author

TGFβ activity stabilizes ACC1 to increase de novo lipogenesis in metabolic liver disease.

Molecular metabolism·2026

関連する実験動画

Updated: Dec 18, 2025

SA-&#946;-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

24.8K

老化性CAR T細胞は老化に関連した病態を逆転させる

Corina Amor1,2, Judith Feucht3,4, Josef Leibold2

  • 1Louis V. Gerstner Jr Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Nature
|June 20, 2020
PubMed
まとめ

ウロキナーゼ型プラズミノゲン活性化受容体 (uPAR) を標的とする化学抗原受容体 (CAR) T細胞は老化細胞を効果的に排除する. この老化アプローチは,年齢関連の疾患の治療の可能性を示し,臨床前モデルでの生存率を改善します.

さらに関連する動画

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.4K
Techniques to Induce and Quantify Cellular Senescence
06:51

Techniques to Induce and Quantify Cellular Senescence

Published on: May 1, 2017

34.7K

関連する実験動画

Last Updated: Dec 18, 2025

SA-&#946;-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

24.8K
Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.4K
Techniques to Induce and Quantify Cellular Senescence
06:51

Techniques to Induce and Quantify Cellular Senescence

Published on: May 1, 2017

34.7K

科学分野:

  • 細胞生物学
  • 免疫療法
  • 老化に関する研究

背景:

  • 細胞の老化は 安定した細胞循環停止状態で 腫瘍抑制と傷の治癒に 二重の役割を果たします
  • 衰老細胞の異常な蓄積は 慢性的な炎症を引き起こし 繊維症や骨格関節炎などの 年齢関連疾患に寄与します
  • 衰老細胞の除去 (衰老分解) は,臨床前試験において,病気の症状の改善と寿命の延長に有望であることが示されています.

研究 の 目的:

  • セノリチス剤としてのキメリック抗原受容体 (CAR) T細胞の治療の可能性を調査する.
  • CAR T細胞媒介による除去のための老化細胞の特定の標的を特定する.
  • 衰老関連疾患の臨床前モデルにおけるUpar特有のCAR T細胞の有効性を評価する.

主な方法:

  • 細胞表面マーカーの特定は,老化細胞に広く誘発されます.
  • ウロキナーゼ型プラズミノゲン活性化受容体 (uPAR) 固有のCAR T細胞の発達と特徴づけ
  • 肺アデノカルシノーマと肝繊維症のモデルにおけるPAR特異性CART細胞のインビトロおよびインビボ検査

主要な成果:

  • uPARは,細胞の老化中に広く誘発される細胞表面タンパク質として特定されました.
  • uPAR特異のCAR T細胞は,老化細胞の効率的な消去を in vitro および in vivo で実証した.
  • UPARを標的としたCAR T細胞治療は,薬剤誘発性肺腺癌のマウスで生存期間を延長し,肝繊維症のモデルで組織ホメオスタシスを回復させた.

結論:

  • uPARは老朽化した細胞にとって有効な治療標的である.
  • uPARを標的とする老化性CAR T細胞は,老化に関連した疾患に対する有望な治療戦略です.
  • このアプローチは,がんの合併症から慢性繊維性疾患まで様々な疾患の治療に役立つ可能性があります.